We were not able to detect any differences in the functionality of FH derived from SP-HUS patients compared to control FH, as measured by FH’s ability to degrade C3b into iC3b and to regulate complement on the sheep erythrocyte surface. This evidence concerns the gene C3 and hemolytic-uremic syndrome.